"HN Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoprotein from Sendai, para-influenza, Newcastle Disease, and other viruses that participates in binding the virus to cell-surface receptors. The HN protein possesses both hemagglutinin and neuraminidase activity.
| Descriptor ID |
D015707
|
| MeSH Number(s) |
D12.776.964.970.880.350 D23.050.327.461.350
|
| Concept/Terms |
HN Protein- HN Protein
- Protein, HN
- HANA Glycoprotein
- Glycoprotein, HANA
- Hemagglutinin-Neuraminidase Glycoprotein
- Glycoprotein, Hemagglutinin-Neuraminidase
- Hemagglutinin Neuraminidase Glycoprotein
|
Below are MeSH descriptors whose meaning is more general than "HN Protein".
Below are MeSH descriptors whose meaning is more specific than "HN Protein".
This graph shows the total number of publications written about "HN Protein" by people in this website by year, and whether "HN Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 0 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 3 | 0 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HN Protein" by people in Profiles.
-
Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies. Nat Microbiol. 2024 Aug; 9(8):2128-2143.
-
Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus. J Infect Dis. 1999 Oct; 180(4):1324-7.
-
RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J Virol. 1999 Sep; 73(9):7262-70.
-
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol. 1999 Feb; 73(2):871-7.
-
Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis. 1998 Apr; 177(4):1073-6.
-
Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J. 1998 Mar; 17(3):217-24.
-
The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J Virol. 1997 Aug; 71(8):5814-9.
-
Cloning, expression and functional activities of a single chain antibody fragment directed to fusion protein of respiratory syncytial virus. Immunotechnology. 1996 Sep; 2(3):219-28.
-
Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis. 1996 Aug; 174(2):256-61.
-
Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J. 1996 Jan; 15(1):23-31.